Shots:
- Alligator to receive up front & research support payments. If Orion exercises its options to continue the development and commercialization of the product then Alligator will be further eligible to receive $548.41M as development, approval, and sales milestone for all three product candidates along with royalties
- The focus of the collaboration is to discover three novel bispecific Abs directed towards immuno-oncology targets, selected by Orion
- Following the collaboration, Alligator will use its phage display libraries and RUBY bispecific platform to develop immuno-oncology product candidates
Click here to read full press release/ article | Ref: Alligator Bioscience | Image: Alligator Bioscience
The post Orion Signs a License and Research Agreement with Alligator to Develop Bispecific Antibody for the Treatment of Cancer first appeared on PharmaShots.
